Cadila Pharmaceuticals Ltd. – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Cadila Pharmaceuticals Ltd. - Product Pipeline Review - H2 2011” provides data on the Cadila Pharmaceuticals Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cadila Pharmaceuticals Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cadila Pharmaceuticals Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Cadila Pharmaceuticals Ltd. - Product Pipeline Review - H2 2011” provides data on the Cadila Pharmaceuticals Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cadila Pharmaceuticals Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cadila Pharmaceuticals Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Cadila Pharmaceuticals Ltd. - Brief Cadila Pharmaceuticals Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cadila Pharmaceuticals Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cadila Pharmaceuticals Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cadila Pharmaceuticals Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Cadila Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cadila Pharmaceuticals Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cadila Pharmaceuticals Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cadila Pharmaceuticals Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cadila Pharmaceuticals Ltd. and identify potential opportunities in those areas.
Cadila Pharmaceuticals Ltd. Snapshot
Cadila Pharmaceuticals Ltd. Overview
Key Information
Key Facts
Cadila Pharmaceuticals Ltd. – Research and Development Overview
Key Therapeutic Areas
Cadila Pharmaceuticals Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Cadila Pharmaceuticals Ltd. – Pipeline Products Glance
Cadila Pharmaceuticals Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cadila Pharmaceuticals Ltd. – Drug Profiles
Mycobacterium w
Product Description
Mechanism of Action
R&D Progress
Mycobacterium w + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Mycobacterium w + Paclitaxel + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Cadila Pharmaceuticals Ltd. – Pipeline Analysis
Cadila Pharmaceuticals Ltd. – Pipeline Products by Therapeutic Class
Cadila Pharmaceuticals Ltd. - Pipeline Products By Target
Cadila Pharmaceuticals Ltd. – Pipeline Products by Route of Administration
Cadila Pharmaceuticals Ltd. – Pipeline Products by Molecule Type
Cadila Pharmaceuticals Ltd. - Dormant Projects
Cadila Pharmaceuticals Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CADI-05
Cadila Pharmaceuticals Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 31, 2009: Cadila Pharmaceuticals Launches Risorine For Treatment Of Tuberculosis
May 09, 2009: Cadila Pharmaceuticals To Launch Polycap
Financial Deals Landscape
Cadila Pharmaceuticals Ltd., Deals Summary
Cadila Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Novavax Forms Joint Venture Company With Cadila Pharmaceuticals
StemCyte Forms Joint Venture With Apollo Hospitals And Cadila Pharmaceuticals
Equity Offering
Novavax Completes Private Placement Of $11 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Cadila Pharmaceuticals Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline by Stage of Development, H2 2011
Cadila Pharmaceuticals Ltd. – Monotherapy Products in Pipeline, H2 2011
Cadila Pharmaceuticals Ltd. – Combination Treatment Modalities in Pipeline, H2 2011
Cadila Pharmaceuticals Ltd. - Phase II, H2 2011
Cadila Pharmaceuticals Ltd. - Phase I, H2 2011
Cadila Pharmaceuticals Ltd. - Pipeline By Therapeutic Class, H2 2011
Cadila Pharmaceuticals Ltd. - Pipeline By Target, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Route of Administration, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Molecule Type, H2 2011
Cadila Pharmaceuticals Ltd. - Dormant Developmental Projects, 2010
Cadila Pharmaceuticals Ltd. - Discontinued Pipeline Products, 2010
Cadila Pharmaceuticals Ltd., Other Locations
Cadila Pharmaceuticals Ltd., Deals Summary
Novavax Forms Joint Venture Company With Cadila Pharmaceuticals
StemCyte Forms Joint Venture With Apollo Hospitals And Cadila Pharmaceuticals
Novavax Completes Private Placement Of $11 Million
LIST OF FIGURES
Cadila Pharmaceuticals Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline by Stage of Development, H2 2011
Cadila Pharmaceuticals Ltd. – Monotherapy Products in Pipeline, H2 2011
Cadila Pharmaceuticals Ltd. – Combination Treatment Modalities in Pipeline, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Therapeutic Class, H2 2011
Cadila Pharmaceuticals Ltd. - Pipeline By Target, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Route of Administration, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Molecule Type, H2 2011
Cadila Pharmaceuticals Ltd. Overview
Key Information
Key Facts
Cadila Pharmaceuticals Ltd. – Research and Development Overview
Key Therapeutic Areas
Cadila Pharmaceuticals Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Cadila Pharmaceuticals Ltd. – Pipeline Products Glance
Cadila Pharmaceuticals Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cadila Pharmaceuticals Ltd. – Drug Profiles
Mycobacterium w
Product Description
Mechanism of Action
R&D Progress
Mycobacterium w + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Mycobacterium w + Paclitaxel + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Cadila Pharmaceuticals Ltd. – Pipeline Analysis
Cadila Pharmaceuticals Ltd. – Pipeline Products by Therapeutic Class
Cadila Pharmaceuticals Ltd. - Pipeline Products By Target
Cadila Pharmaceuticals Ltd. – Pipeline Products by Route of Administration
Cadila Pharmaceuticals Ltd. – Pipeline Products by Molecule Type
Cadila Pharmaceuticals Ltd. - Dormant Projects
Cadila Pharmaceuticals Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CADI-05
Cadila Pharmaceuticals Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 31, 2009: Cadila Pharmaceuticals Launches Risorine For Treatment Of Tuberculosis
May 09, 2009: Cadila Pharmaceuticals To Launch Polycap
Financial Deals Landscape
Cadila Pharmaceuticals Ltd., Deals Summary
Cadila Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Novavax Forms Joint Venture Company With Cadila Pharmaceuticals
StemCyte Forms Joint Venture With Apollo Hospitals And Cadila Pharmaceuticals
Equity Offering
Novavax Completes Private Placement Of $11 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Cadila Pharmaceuticals Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline by Stage of Development, H2 2011
Cadila Pharmaceuticals Ltd. – Monotherapy Products in Pipeline, H2 2011
Cadila Pharmaceuticals Ltd. – Combination Treatment Modalities in Pipeline, H2 2011
Cadila Pharmaceuticals Ltd. - Phase II, H2 2011
Cadila Pharmaceuticals Ltd. - Phase I, H2 2011
Cadila Pharmaceuticals Ltd. - Pipeline By Therapeutic Class, H2 2011
Cadila Pharmaceuticals Ltd. - Pipeline By Target, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Route of Administration, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Molecule Type, H2 2011
Cadila Pharmaceuticals Ltd. - Dormant Developmental Projects, 2010
Cadila Pharmaceuticals Ltd. - Discontinued Pipeline Products, 2010
Cadila Pharmaceuticals Ltd., Other Locations
Cadila Pharmaceuticals Ltd., Deals Summary
Novavax Forms Joint Venture Company With Cadila Pharmaceuticals
StemCyte Forms Joint Venture With Apollo Hospitals And Cadila Pharmaceuticals
Novavax Completes Private Placement Of $11 Million
LIST OF FIGURES
Cadila Pharmaceuticals Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline by Stage of Development, H2 2011
Cadila Pharmaceuticals Ltd. – Monotherapy Products in Pipeline, H2 2011
Cadila Pharmaceuticals Ltd. – Combination Treatment Modalities in Pipeline, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Therapeutic Class, H2 2011
Cadila Pharmaceuticals Ltd. - Pipeline By Target, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Route of Administration, H2 2011
Cadila Pharmaceuticals Ltd. – Pipeline By Molecule Type, H2 2011
